Neuroendocrine Tumors (NETs): The Slow-Growing Cancers That Are Often Misdiagnosed
When 48-year-old Sarah developed episodic facial flushing and explosive diarrhea, her primary care doctor diagnosed irritable bowel syndrome and prescribed antispasmodics. When symptoms persisted two years later, a gastroenterologist attributed them to “stress-related bowel dysfunction.” Only when Sarah developed severe right-sided heart murmur did a cardiologist order echocardiogram revealing valvular damage—leading to imaging that discovered liver metastases from small bowel neuroendocrine tumor. “Four years of symptoms,” Sarah recalled bitterly. “Four years seeing doctors who never considered carcinoid syndrome because they’d never seen a case.” Neuroendocrine tumors (NETs) are rare, slow-growing neoplasms that develop from neuroendocrine cells, which are hormone-producing cells found throughout the body. NETs affect about 6 in 100,000 people worldwide. Many NETs take years to diagnose because symptoms resemble common conditions like irritable bowel syndrome, asthma, or acid reflux. Studies show that patients wait an average of 52 months (over 4 years) from symptom onset to diagnosis. Despite metastatic disease and the carcinoid syndrome that can accompany it, NETs are slow growing, and survival of 10 to 15 years is not unusual. Understanding why these indolent tumors evade diagnosis for years—and how advanced molecular imaging finally reveals them—provides critical insights into managing one of oncology’s most deceptive cancers. Neuroendocrine Tumors: The Silent Cancer on the Rise – Breakthroughs in Diagnosis, Treatment, Survival and Latest 2025 Reaserches – OncoDaily +2
What Are Neuroendocrine Cells and Where Do Tumors Arise?
Neuroendocrine cells constitute a diffuse endocrine system scattered throughout the body—hybrid cells combining nerve cell (neuron) and hormone-secreting (endocrine) characteristics. These cells produce hormones and neuropeptides regulating digestion, blood pressure, breathing, metabolism. High concentrations exist in: gastrointestinal tract (stomach, small intestine, appendix, colon), lungs and bronchi, pancreas, thyroid and parathyroid glands, adrenal medulla, and pituitary gland. Gastrointestinal neuroendocrine tumors: NETs most commonly start in your gastrointestinal tract. Most start in your intestines, rectum or appendix. GI-NETs used to be called carcinoid tumors. Lung neuroendocrine tumors: These tumors start in your lungs or bronchi, the tubes that carry air from your windpipe to your lungs. They’re the second most common type of NET and were also once called carcinoid tumors. Pancreatic neuroendocrine tumors: These tumors start in your pancreas and are a type of pancreatic cancer. P-NETs are the third most common type of NET. Historical terminology confusion: “carcinoid” (meaning “carcinoma-like”) originally described all slow-growing neuroendocrine tumors. Modern classification abandoned this term, now using specific anatomical designations (gastroenteropancreatic NETs, bronchopulmonary NETs, etc.) with grading based on proliferation rate. Cleveland Clinic
Functional vs. Nonfunctional: The Hormone Problem
Functional NETs (20-30% of cases): actively secrete hormones producing distinctive clinical syndromes. Examples: Carcinoid syndrome (serotonin-secreting)—most common functional syndrome. Insulinomas (insulin-secreting)—dangerous hypoglycemia, confusion, seizures. Gastrinomas (gastrin-secreting)—Zollinger-Ellison syndrome with severe ulcers, diarrhea. VIPomas (vasoactive intestinal peptide)—watery diarrhea syndrome, dehydration, hypokalemia. Glucagonomas (glucagon-secreting)—necrolytic migratory erythema (characteristic rash), diabetes, weight loss. Carcinoid Syndrome: Flushing, diarrhea, wheezing, and heart valve damage. Insulinomas: Dangerous low blood sugar levels. Gastrinomas: Severe acid reflux and stomach ulcers. Early detection allows doctors to manage these hormone-related symptoms before they lead to life-threatening complications. Nonfunctional NETs (70-80% of cases): produce no hormones or insufficient amounts causing symptoms. As the majority of NETs are non-functional, they present late usually with symptoms of mass effect or liver metastasis. Remain clinically silent until tumor large enough to cause: abdominal pain from mass effect, bowel obstruction, liver metastases (hepatomegaly, right upper quadrant pain), weight loss, or incidental discovery on imaging for other reasons. The diagnostic implication: functional NETs diagnosed earlier due to hormonal symptoms (average 2-3 years from symptom onset); nonfunctional NETs diagnosed later with larger tumor burden and metastases (average 5-7 years, often stage 4 at presentation). Oncodailynih
Carcinoid Syndrome: The Classic Presentation
Carcinoid syndrome develops in patients with metastatic disease, especially those with liver metastasis, and it is present in about 10% of patients with NETs. Carcinoid syndrome manifestations are flushing (94%), diarrhea (78%), abdominal cramping (50%), valvular heart disease (50%), telangiectasia (25%), wheezing (15%), and edema (19%). The hallmark symptoms of carcinoid syndrome are flushing and diarrhea; atypical signs and symptoms can include wheezing, abdominal pain, valvular heart disease, telangiectasias, pellagra, and the complications of mesenteric fibrosis, including ureteral obstruction, bowel obstruction, and bowel ischemia. These symptoms are mediated by the release of serotonin, histamine, kallikrein, prostaglandins, and tachykinins. Carcinoid syndrome can develop in up to 40% of patients with NETs. The mechanism: gastrointestinal NETs produce serotonin metabolized by liver before reaching systemic circulation—prevents symptoms. When tumor metastasizes to liver, serotonin released directly into hepatic veins bypassing first-pass metabolism, flooding systemic circulation. Flushing (94% of carcinoid syndrome): sudden warmth and redness of face, neck, upper chest. Flushing associated with carcinoid syndrome is distinctive, reddish-brown with variegated margination that manifests as wheals over the entire body including palms and soles. It is usually triggered by foods and adrenergic stimuli such as pain and anger. Episodes last seconds to minutes, triggered by alcohol, spicy foods, emotional stress, physical exertion. Diarrhea (78%): explosive, watery, non-bloody, 5-10+ bowel movements daily. Diarrhea in carcinoid syndrome is explosive, watery, non-bloody, and accompanied by abdominal cramping. Often awakens patient at night. Causes profound dehydration, electrolyte imbalances, malabsorption. Carcinoid heart disease (50%): serotonin damages right-sided heart valves (tricuspid, pulmonic) causing regurgitation, stenosis. Leads to right heart failure—peripheral edema, ascites, liver congestion. Lesions of the left side of the heart, which have been reported with bronchial NETs, are rare because serotonin is destroyed during passage through the lungs. Left heart valves typically spared (serotonin inactivated in lungs before reaching left heart). Wheezing/bronchospasm (15%): serotonin-induced bronchoconstriction mimicking asthma. Pellagra (rare): niacin deficiency occurs when tryptophan diverted to serotonin production rather than niacin synthesis. Causes dermatitis, diarrhea, dementia. Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review +2 + 3
The Misdiagnosis Problem: Years of Wrong Diagnoses
Many NETs take years to diagnose because symptoms resemble common conditions like irritable bowel syndrome, asthma, or acid reflux. Studies show that patients wait an average of 52 months (over 4 years) from symptom onset to diagnosis. This delay increases the risk of tumor spread and limits treatment options. Common misdiagnoses delaying NET discovery: Irritable bowel syndrome: chronic diarrhea, abdominal cramping attributed to functional bowel disorder. Years of dietary modifications, probiotics, antispasmodics before imaging reveals liver metastases. Menopause/anxiety: episodic flushing dismissed as hot flashes in women 40s-50s despite absence of other menopausal symptoms. Asthma: wheezing treated with bronchodilators, inhaled corticosteroids—partial response confuses picture. Rosacea: persistent facial flushing attributed to skin condition rather than systemic disease. Gastroesophageal reflux disease: abdominal pain, diarrhea managed empirically with proton pump inhibitors for years. The diagnostic barriers: symptoms nonspecific and intermittent (patients appear well between episodes), primary care physicians rarely encounter NETs (incidence 6 per 100,000—average GP might see one case in career), standard blood tests (CBC, metabolic panel) usually normal even with advanced disease, and no screening protocols exist even for high-risk populations. The consequence: 50-70% of gastroenteropancreatic NETs already metastatic at diagnosis—often liver, lymph nodes, bone. Earlier diagnosis potentially allows curative surgery; delayed diagnosis means palliative treatment only. Oncodaily
Diagnostic Tools: From Blood Tests to Molecular Imaging
Biochemical markers: Chromogranin A is one of the most widely used general biomarkers for NETs. It is secreted by neuroendocrine cells and is often elevated in patients with well-differentiated tumors. 5-Hydroxyindoleacetic acid is the primary metabolite of serotonin and is measured in a 24-hour urine collection. It is particularly useful for diagnosing serotonin-producing carcinoid tumors, especially those of the midgut, and can help confirm the presence of carcinoid syndrome. Serum chromogranin A, a well-established marker for NETs, is helpful in the diagnosis of NETs. Combining measurements of serum chromogranin A with 24-hour urine 5-HIAA results in increased overall test sensitivity in patients with carcinoid syndrome. Chromogranin A (CgA): protein released by neuroendocrine cells; elevated in 60-80% of NETs. Limitations: also elevated in proton pump inhibitor use, chronic atrophic gastritis, renal failure, heart failure—false positives common. Should be checked off PPIs for 2 weeks if possible. 24-hour urine 5-HIAA: serotonin metabolite; normal <10 mg/day, carcinoid syndrome typically >50 mg/day. High sensitivity/specificity for serotonin-producing midgut NETs. Must avoid certain foods (bananas, avocados, tomatoes) and medications (guaifenesin, acetaminophen) before collection—interfere with assay. Pancreatic-specific hormones: insulin (insulinomas), gastrin (gastrinomas), glucagon (glucagonomas), VIP (VIPomas)—measured when functional pancreatic NET suspected. Conventional imaging: CT and MRI visualize primary tumor and metastases. NETs often appear as hypervascular masses (bright on arterial phase contrast). Liver metastases common—typically multiple, well-circumscribed. Functional imaging—the game changer: Gallium-68 DOTATATE PET/CT scans can detect even small NETs. Imaging tests help visualize the cancer to identify a tumor’s location and find out whether it has metastasized. These include a computed tomography scan, magnetic resonance imaging and a specialized positron emission tomography scan called a dotatate scan, which may help detect neuroendocrine tumors. Ga-68 DOTATATE PET/CT: revolutionized NET imaging. Radiotracer binds somatostatin receptors (expressed on >90% of NETs), lights up tumors throughout body. Detects lesions <5mm missed by CT/MRI. Standard imaging for NET staging, surveillance, treatment planning. Replaces older octreotide scans (inferior resolution, longer imaging time). City of Hope + 3
The Grading System: Ki-67 and Tumor Behavior
NETs classified by proliferation rate using Ki-67 index (percentage of actively dividing cells) and mitotic count: Grade 1 (G1): Ki-67 <3%, mitotic count <2 per 10 high-power fields. Slow-growing, well-differentiated, best prognosis. Grade 2 (G2): Ki-67 3-20%, mitotic count 2-20. Intermediate behavior, moderately differentiated. Grade 3 (G3): Ki-67 >20%, mitotic count >20. Rapidly growing, poorly differentiated (neuroendocrine carcinoma), worst prognosis. Patients with grade 1 or 2 tumors had a significantly longer median overall survival of 97 months compared to 74.5 months for grade 3 tumors. The grade paradox: even G1/G2 NETs metastasize (50-70% present with metastases) but survival prolonged due to slow doubling time. Patients live years/decades with metastatic G1/G2 disease. G3 behaves more like aggressive carcinoma—shorter survival, requires intensive chemotherapy. Clinical implications: grade determines treatment approach. G1/G2 managed with surgery, somatostatin analogs, PRRT, liver-directed therapies. G3 requires platinum-based chemotherapy, often combined with etoposide—similar to small cell lung cancer regimens. Frontiers
Treatment Revolution: PRRT Changes the Game
Peptide receptor radionuclide therapy was demonstrated in randomized controlled trials. The recently published NETTER-2 trial evaluated the efficacy of PRRT in combination with octreotide LAR as first-line therapy for a sub-group of grade 2 (proliferation marker Ki-67 ≥10%) and grade 3 gastroenteropancreatic NET. It demonstrated significant improvements in median progression-free survival, positioning it as a potential new standard of care in the first-line setting. PRRT was well tolerated by all patients; no grade 3 or grade 4 hematotoxicity occurred, and no clinically significant decline in renal function was observed. There was no hepatotoxicity. In the group with 18F-FDG uptake scored as 0-2, the median progression-free survival was 24.3 months and the median overall survival was 41.6 months. Overall survival for the entire cohort was 79 months, with patients receiving 4+ cycles of PRRT having an overall survival of 87 months and those receiving 5+ cycles achieving an overall survival of 100 months. PRRT mechanism: Lu-177-DOTATATE (Lutathera)—radioactive isotope attached to somatostatin analog. Binds somatostatin receptors on NET cells. Delivers targeted radiation directly to tumor—kills cancer cells while sparing normal tissues. Treatment protocol: four infusions given 8 weeks apart (standard course). Outpatient procedure—4-6 hour infusion with kidney protection (amino acid infusion preventing radiotracer uptake in kidneys). Efficacy: NETTER-1 trial (landmark 2017 study): progression-free survival 28.4 months with PRRT versus 8.4 months with high-dose octreotide alone. Disease control rate 85%. NETTER-2 trial (2024): demonstrated benefit as first-line therapy for higher-grade NETs. Side effects: generally well-tolerated. Nausea/fatigue during infusions (manageable). Low risk serious toxicity: bone marrow suppression (5-10%), kidney damage (rare with proper precautions), secondary leukemia (very rare, <1%). The paradigm shift: PRRT transformed metastatic NETs from progressive disease with limited options to manageable chronic condition. Patients living 5-10+ years with good quality of life now commonplace. Other treatments: Somatostatin analogs (SSAs): octreotide, lanreotide—control hormonal symptoms (carcinoid syndrome), also have antiproliferative effect slowing tumor growth. Monthly or tri-monthly injections. First-line for many NETs. Everolimus (mTOR inhibitor): oral targeted therapy blocking cell growth pathways. FDA-approved for pancreatic and GI NETs. Sunitinib: oral multi-kinase inhibitor for pancreatic NETs. Blocks blood vessel growth feeding tumors. Liver-directed therapies: for liver-dominant metastases—radiofrequency ablation, transarterial chemoembolization (TACE), selective internal radiation (radioembolization). Surgery: complete resection curative for localized disease; even with metastases, debulking primary tumor (cytoreductive surgery) improves symptoms, outcomes. Chemotherapy: reserved for G3 neuroendocrine carcinomas—platinum-based regimens (cisplatin/carboplatin + etoposide). Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients – PubMed +2
Survival: The Chronic Disease Model
Despite metastatic disease and the carcinoid syndrome that can accompany it, NETs are slow growing, and survival of 10 to 15 years is not unusual. Five-year survival by stage and grade: Localized disease (30-40% at diagnosis): G1/G2 pancreatic NETs 93% five-year survival; G1/G2 small bowel NETs 97%; appendiceal carcinoids <2cm essentially 100%. Regional disease (lymph node involvement): G1/G2 60-80% five-year survival depending on location. Distant metastases (50-70% at diagnosis): G1 40-60% five-year survival; G2 30-50%; G3 <20%. The paradox: patients with metastatic G1/G2 NETs often live 5-15+ years—treating as chronic disease like diabetes rather than terminal cancer. The contemporary approach: sequential therapies over many years. Start SSAs (symptom control, slow growth); add PRRT when progression (87-100 month survival with 4-5 cycles); utilize liver-directed therapies for hepatic-dominant disease; reserve everolimus/sunitinib for later progression; repeat PRRT if tumors remain somatostatin receptor-positive. Patients cycling through treatments over decade+ not uncommon. The quality of life focus: with modern therapies controlling disease progression, emphasis shifts to managing carcinoid syndrome symptoms, preventing carcinoid heart disease, maintaining nutrition despite chronic diarrhea, and addressing psychological burden of chronic cancer diagnosis. nih
Frequently Asked Questions
Q1: I’ve had chronic diarrhea and intermittent flushing for 3 years diagnosed as IBS. Could this be carcinoid syndrome?
Possibly, though IBS remains far more common. Key distinguishing features favor carcinoid syndrome: flushing episodes (IBS doesn’t cause flushing), explosive watery diarrhea waking you at night (IBS diarrhea rarely nocturnal), symptoms unresponsive to typical IBS treatments (antispasmodics, dietary modifications, probiotics), progressive worsening over months/years (IBS typically fluctuates), and onset age >40 (IBS usually begins 20s-30s). You should request: 24-hour urine 5-HIAA collection (most specific test for serotonin-producing NETs), serum chromogranin A (general NET marker—must be off proton pump inhibitors 2 weeks), and abdominal/pelvic CT or MRI with contrast (looking for small bowel or pancreatic mass, liver lesions). If biochemical markers elevated or imaging shows masses, Ga-68 DOTATATE PET/CT provides definitive NET staging. Don’t accept IBS diagnosis indefinitely if symptoms persist/worsen—advocate for workup, consider gastroenterology referral at center with NET expertise.
Q2: My father was just diagnosed with metastatic small bowel NET with liver lesions. Does this mean he’s terminal?
Not at all—metastatic NETs behave very differently from metastatic colon, lung, or pancreatic adenocarcinomas. Critical questions determining prognosis: What’s the tumor grade? G1/G2 (Ki-67 <20%) have indolent course—median survival 5-10+ years even with liver metastases. G3 (Ki-67 >20%) more aggressive but still treatable. Does tumor express somatostatin receptors? If DOTATATE PET-positive, eligible for PRRT—dramatically extends survival. What’s the liver tumor burden? Even extensive liver involvement manageable with PRRT, liver-directed therapies. Modern treatment sequence: start somatostatin analog (octreotide/lanreotide) for symptom control and tumor stabilization; PRRT when disease progresses (87-100 month median survival with 4-5 cycles); liver-directed therapy (ablation, embolization) for symptomatic liver metastases; oral targeted therapies (everolimus, sunitinib) for subsequent progression. Many patients cycle through these treatments over 10-15 years maintaining good quality of life. Metastatic G1/G2 NETs managed as chronic disease rather than terminal cancer. Encourage your father to seek care at NET center of excellence—specialized expertise improves outcomes.
Q3: I need PRRT but my insurance denied it saying it’s experimental. How do I fight this?
PRRT (Lu-177-DOTATATE/Lutathera) received FDA approval January 2018 for gastroenteropancreatic NETs—it’s NOT experimental. Insurance denials typically occur from: outdated policy language (predating 2018 approval), confusion with older Y-90-based PRRT (truly was investigational), or narrow interpretation of FDA indication. Fight denial with: Obtain detailed denial letter explaining specific reason. Request peer-to-peer review: have your oncologist speak directly with insurance medical director explaining FDA approval, NETTER-1 trial data, standard-of-care status. Submit appeal with documentation: FDA approval letter (January 2018), NCCN guidelines listing PRRT as Category 1 recommendation, NETTER-1 publication (New England Journal of Medicine), letter from oncologist detailing your specific case. Involve patient advocates: NET Research Foundation, Carcinoid Cancer Foundation have insurance navigation services. Consider external review: if internal appeals fail, request independent external review (required by law)—success rate 30-50%. Financial assistance: if insurance won’t cover, Lutathera manufacturer (Advanced Accelerator Applications/Novartis) offers patient assistance programs. List price ~$200,000 but rarely paid out-of-pocket. Don’t give up—most denials overturned with proper documentation and persistence. PRRT is established standard-of-care, not experimental.
Q4: What’s the difference between well-differentiated NETs and poorly-differentiated neuroendocrine carcinomas?
These represent opposite ends of neuroendocrine neoplasm spectrum with dramatically different biology and treatment: Well-differentiated NETs (G1/G2, Ki-67 <20%): tumor cells closely resemble normal neuroendocrine cells under microscope; grow slowly over years to decades; express somatostatin receptors (positive DOTATATE PET); often produce functional hormones (carcinoid syndrome, insulinomas); treated with surgery, somatostatin analogs, PRRT; median survival measured in years/decades even when metastatic; behave as chronic manageable disease. Poorly-differentiated neuroendocrine carcinomas (G3, Ki-67 >20%): tumor cells barely resemble normal cells—high-grade, anaplastic appearance; grow rapidly over weeks to months; often don’t express somatostatin receptors (negative DOTATATE PET, positive FDG-PET); rarely produce hormones; treated like small cell lung cancer—platinum-based chemotherapy (cisplatin + etoposide); median survival measured in months (12-24 even with treatment); behave as aggressive carcinoma. The treatment implication: never assume all NETs managed identically. Well-differentiated NETs benefit from targeted approaches (PRRT, SSAs). Poorly-differentiated carcinomas require chemotherapy—PRRT ineffective. Pathology grade (Ki-67) determines entire treatment strategy.
Q5: My chromogranin A is elevated at 250 but imaging shows no tumor. Should I be worried?
Elevated chromogranin A without imaging evidence of tumor is common and usually benign. CgA elevated in numerous non-cancerous conditions: Proton pump inhibitors (Prilosec, Nexium, Protonix): most common cause false-positive CgA. PPIs reduce stomach acid causing G-cells to produce more CgA compensatorily. CgA often 2-5 fold elevated. Solution: stop PPI for 2 weeks (switch to H2-blocker like famotidine if needed), recheck CgA. Chronic atrophic gastritis: autoimmune or H. pylori-induced gastritis damages stomach lining, triggers CgA release. Renal impairment: kidney dysfunction reduces CgA clearance, causing accumulation. Heart failure, hypertension: cardiovascular conditions can elevate CgA. Inflammatory bowel disease: Crohn’s, ulcerative colitis occasionally raise CgA. If CgA remains elevated off PPIs with negative imaging (CT/MRI AND Ga-68 DOTATATE PET), NET extremely unlikely. Reasonable approach: recheck CgA every 6-12 months; repeat imaging if CgA rising or new symptoms develop; but don’t undergo invasive procedures (endoscopy, biopsy) chasing asymptomatic mild CgA elevation. True NETs typically CgA >500-1,000 with positive DOTATATE PET. Your 250 with negative imaging most likely benign elevation from one of the conditions above.
Disclaimer
This article adapts publicly available information from reputable cancer research organizations and medical databases. This content is for informational and educational purposes only and does not constitute medical advice. ObserverVoice.com is a news and information platform — not a healthcare provider. Decisions about neuroendocrine tumor screening, diagnosis, and treatment should be made in consultation with qualified physicians, oncologists, and endocrinologists who can evaluate your individual symptoms, test results, and health status. If you have symptoms concerning for neuroendocrine tumors or carcinoid syndrome, please consult with your healthcare team promptly.
References
- OncoDaily. Neuroendocrine Tumors: The Silent Cancer on the Rise. https://oncodaily.com/oncolibrary/cancer-types/neuroendocrine-tumors
- PMC. Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053559/
- Cleveland Clinic. Neuroendocrine Tumors: Symptoms & Treatment. https://my.clevelandclinic.org/health/diseases/22006-neuroendocrine-tumors-net
- Merck Manual. Gastrointestinal Neuroendocrine Tumors and Carcinoid Syndrome. https://www.merckmanuals.com/professional/endocrine-and-metabolic-disorders/gastrointestinal-and-pancreatic-neuroendocrine-tumors-nets/gastrointestinal-neuroendocrine-tumors-and-carcinoid-syndrome
- PMC. Impact of functionality and grading on survival in pancreatic neuroendocrine tumor patients receiving PRRT. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037364/
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
